Sanofi GCVRZ 深 沪
已收盘 03-26 16:00:00 美东时间
0.8711
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.8711
- 总市值 1113.52亿
- 52周最高 0.882
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.43
- 委 比 0.00%
- 总股本 1278.30亿
- 历史最高 0.882
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.153
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多药物受理最新动态：Sanofi Winthrop Industrie尼塞韦单抗注射液进口申请获受理
国家药品监督管理局药品审评中心数据显示，2026年8月7日，Sanofi Winthrop Industrie的尼塞韦单抗注射液申请已获受理，受理号为JXSS...
08-07 14:15
Sanofi India posts robust Q2 2026 results, revamps board committees
An announcement from Sanofi India Limited ( ($IN:SANOFI) ) is now available. Sa...
08-04 23:16
Sanofi’s MenQuadfi approved in EU for infants against meningococcal disease
Sanofi (SNY) received European Commission approval to expand MenQuadfi’s indication to infants aged six weeks and older for protection against invasive meningococcal disease caused by Neisseria mening...
08-04 17:12
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Nurix Therapeutics and Roche have initiated a global Phase 3 trial, DAYBreak CLL-306, to compare bexobrutideg, a BTK degrader, with pirtobrutinib in relapsed/refractory CLL/SLL patients who previously received covalent BTK inhibitors. The study aims to demonstrate bexobrutideg's superiority, with primary endpoints of ORR and PFS. This marks the first Phase 3 trial for bexobrutideg, targeting a new treatment approach for CLL.
08-04 05:00
Sanofi Says Weak Decision-Making Hurt Pipeline, Promises More Disciplined R&D
Sanofi SA (NASDAQ:SNY) on Thursday reported second-quarter sales of $13.482 billion (11.597 billion euros), beating the consensus of $12.65 billion. Sales increased 16% year over year, up 17.8% in constant currency. Dupixent Drives Growth While Vaccines Sales Decline Dupixent sales increased by 37.6...
07-31 02:45
赛诺菲CEO坦言管线挑战，股价大幅下跌
法国制药巨头赛诺菲（Sanofi）股价周四在欧洲午后交易中下跌9%，有望创下近三年来最大单日跌幅。此前，公司新任首席执行官贝伦·加里霍（Belen Gar...
07-30 23:07
药物受理最新动态：Sanofi S.r.l.注射用拉布立海进口申请获受理
国家药品监督管理局药品审评中心数据显示，2026年7月30日，Sanofi S.r.l.的注射用拉布立海申请已获受理，受理号为JTS2600135。 受...
07-30 21:15
Sanofi Sees FY2026 Sales $55.789B vs $55.850B Est
Sanofi (NASDAQ:SNY) sees FY2026 sales of $55.789 billion vs $55.850 billion analyst estimate.
07-30 21:03
Sanofi Q2 Adj. EPS $1.21 Beats $1.09 Estimate, Sales $13.482B Beat $12.650B Estimate
Sanofi (NASDAQ:SNY) reported quarterly earnings of $1.21 per share which beat the analyst consensus estimate of $1.09 by 11.01 percent. This is a 34.44 percent increase over earnings of $0.90 per share from the same period last year. The company reported quarterly sales of $13.482 billion which beat...
07-30 13:34
Sanofi Targets Dual RSV–HMPV Opportunity With Fresh Phase 1/2 Vaccine Study
Sanofi SA ($SNY) announced an update on their ongoing clinical study. Sanofi SA...
07-30 00:31
